A bill to amend the Internal Revenue Code of 1986 to provide a tax credit for medical research related to developing qualified infectious disease products.

referredUnited States· United States Congress· EN

Introduced

14 November 2007

Last action

—

Status

Read twice and referred to the Committee on Finance.

Summary

Amends the Internal Revenue Code to allow a general business tax credit for 50% of expenses paid for research and development of any qualified infectious disease product. Defines "qualified infectious disease product" as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

Introduced in Senate (text)

View file Download file

Introduced in Senate (text)
Introduced in Senate · EN · 14 November 2007
View Download Open at official source
Introduced in Senate (PDF)
Introduced in Senate · EN · 14 November 2007
View Download Open at official source
Introduced in Senate
summary · EN · 14 November 2007
Open at official source

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/bill/110th-congress/senate-bill/2351
Open data entity: https://api.congress.gov/v3/bill/110/s/2351